TRT and Prostate Cancer Risk: The Updated Evidence
Written by Adam Maggio | Medically reviewed by Dr. Mitchell Ross, MD, ABAARM
Current evidence suggests that Testosterone Replacement Therapy (TRT) does not increase the risk of developing prostate cancer in men with healthy prostates, nor does it typically cause progression in carefully selected men with a history of treated prostate cancer. The long-held belief that testosterone fuels prostate cancer is being refined by modern research.
TRT and Prostate Cancer Risk: The Updated Evidence
For decades, the relationship between testosterone and prostate cancer has been a source of significant concern and debate in medical circles. The prevailing dogma, often referred to as the âandrogen hypothesis,â suggested that testosterone fuels prostate cancer growth, leading to a cautious, if not prohibitive, approach to Testosterone Replacement Therapy (TRT) in men with prostate cancer or even those at risk. However, updated evidence and a deeper understanding of prostate physiology have significantly refined this perspective, challenging older assumptions and offering a more nuanced view.
The initial concern stemmed from the observation that androgen deprivation therapy (ADT) effectively treats advanced prostate cancer by lowering testosterone. This led to the logical, but perhaps oversimplified, conclusion that increasing testosterone through TRT would inevitably promote cancer. What we now understand is that the prostate gland, and prostate cancer cells, operate under a âsaturation model.â This means that prostate cells have a finite number of androgen receptors, and once these receptors are saturated with testosterone, further increases in testosterone levels do not lead to additional growth or stimulation [1].
Challenging the Old Paradigm: The Saturation Model
In hypogonadal men, testosterone levels are often below the saturation point for prostate androgen receptors. When TRT is initiated, testosterone levels rise, saturating these receptors. This can lead to a modest, often transient, increase in prostate-specific antigen (PSA) and prostate volume, as discussed in previous articles. However, once saturation is achieved, even supraphysiological levels of testosterone do not appear to further stimulate prostate cancer growth. This is a critical distinction: restoring testosterone to normal physiological levels in hypogonadal men is not the same as providing an unlimited fuel source for cancer.
Recent systematic reviews and meta-analyses have largely failed to demonstrate a causal link between TRT and an increased risk of developing prostate cancer in men without a prior history of the disease [2]. These studies indicate that TRT does not increase the incidence of prostate cancer compared to men not receiving TRT. Furthermore, there's no consistent evidence of increased prostate cancer diagnosis rates in men on TRT.
TRT in Men with a History of Prostate Cancer
Perhaps the most significant shift in understanding concerns men who have been treated for prostate cancer. Historically, TRT was strictly contraindicated in these individuals. However, for carefully selected men who have undergone definitive treatment for localized prostate cancer (e.g., radical prostatectomy or radiation therapy) and have no evidence of recurrence, TRT is increasingly being considered. Studies have shown that TRT can be safely administered to these men, with no increased risk of biochemical recurrence (BCR) or disease progression [3, 4].
This represents a paradigm shift, allowing men who are cured of prostate cancer but suffer from hypogonadal symptoms to benefit from TRT, significantly improving their quality of life. The key here is careful patient selection, thorough counseling, and close monitoring by an experienced urologist or oncologist.
Comparison: Prostate Cancer Risk Perception
| Perspective | Old Paradigm (Pre-2000s) | Updated Evidence (Post-2000s) |
|---|---|---|
| TRT and New PCa Diagnosis | Assumed increased risk | No strong evidence of increased risk in healthy men |
| TRT and Existing PCa Growth | Assumed to fuel growth | Saturation model: no further stimulation beyond saturation |
| TRT Post-PCa Treatment | Strictly contraindicated | Potentially safe in carefully selected, treated men |
Practical Takeaway
If you have low testosterone and are considering TRT, rest assured that current, updated evidence does not support the notion that TRT increases your risk of developing prostate cancer. If you have a history of treated prostate cancer, discuss your options with your urologist or oncologist; TRT may be a safe and beneficial option for you under strict medical supervision. The key is always personalized assessment and careful monitoring.
References
- Michaud, J. E., & Khera, M. (2015). Testosterone and prostate cancer: an evidence-based review of the literature. Translational Andrology and Urology, 4(5), 574â581.
- Harvard Health Publishing. (2024). Appropriate use of testosterone therapy does not appear to raise prostate cancer risk.
- Gibson, J., et al. (2025). Testosterone replacement therapy following definitive treatment for prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases.
- Porena, M., et al. (2025). Testosterone Supplementation After Localized Prostate Cancer: The Current State of the Literature. AUA News, 30(7), 10-12.